274 related articles for article (PubMed ID: 38292211)
1. Propranolol: a new pharmacologic approach to counter retinopathy of prematurity progression.
Pascarella F; Scaramuzzo RT; Pini A; Cammalleri M; Bagnoli P; Ciantelli M; Filippi L
Front Pediatr; 2024; 12():1322783. PubMed ID: 38292211
[TBL] [Abstract][Full Text] [Related]
2. Decoupling Oxygen Tension From Retinal Vascularization as a New Perspective for Management of Retinopathy of Prematurity. New Opportunities From β-adrenoceptors.
Filippi L; Cammalleri M; Amato R; Ciantelli M; Pini A; Bagnoli P; Dal Monte M
Front Pharmacol; 2022; 13():835771. PubMed ID: 35126166
[TBL] [Abstract][Full Text] [Related]
3. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.
Filippi L; Cavallaro G; Fiorini P; Daniotti M; Benedetti V; Cristofori G; Araimo G; Ramenghi L; La Torre A; Fortunato P; Pollazzi L; la Marca G; Malvagia S; Bagnoli P; Ristori C; Dal Monte M; Bilia AR; Isacchi B; Furlanetto S; Tinelli F; Cioni G; Donzelli G; Osnaghi S; Mosca F
BMC Pediatr; 2010 Nov; 10():83. PubMed ID: 21087499
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.
Kaempfen S; Neumann RP; Jost K; Schulzke SM
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011893. PubMed ID: 29499081
[TBL] [Abstract][Full Text] [Related]
5. Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.
Filippi L; Cavallaro G; Berti E; Padrini L; Araimo G; Regiroli G; Bozzetti V; De Angelis C; Tagliabue P; Tomasini B; Buonocore G; Agosti M; Bossi A; Chirico G; Aversa S; Pasqualetti R; Fortunato P; Osnaghi S; Cavallotti B; Vanni M; Borsari G; Donati S; Nascimbeni G; la Marca G; Forni G; Milani S; Cortinovis I; Bagnoli P; Dal Monte M; Calvani AM; Pugi A; Villamor E; Donzelli G; Mosca F
BMC Pediatr; 2017 Jul; 17(1):165. PubMed ID: 28709412
[TBL] [Abstract][Full Text] [Related]
6. Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.
Filippi L; Dal Monte M; Casini G; Daniotti M; Sereni F; Bagnoli P
Med Res Rev; 2015 May; 35(3):619-52. PubMed ID: 25523517
[TBL] [Abstract][Full Text] [Related]
7. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology.
Cayabyab R; Ramanathan R
Neonatology; 2016; 109(4):369-76. PubMed ID: 27251645
[TBL] [Abstract][Full Text] [Related]
8. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy.
Chen J; Joyal JS; Hatton CJ; Juan AM; Pei DT; Hurst CG; Xu D; Stahl A; Hellstrom A; Smith LE
Invest Ophthalmol Vis Sci; 2012 May; 53(6):2968-77. PubMed ID: 22491401
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?
Ozturk MA; Korkmaz L
Int Ophthalmol; 2019 Sep; 39(9):1921-1930. PubMed ID: 30229439
[TBL] [Abstract][Full Text] [Related]
10. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
11. Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity?
Bührer C; Bassler D
Neonatology; 2015; 108(1):49-52. PubMed ID: 25968340
[TBL] [Abstract][Full Text] [Related]
12. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice.
Dal Monte M; Casini G; la Marca G; Isacchi B; Filippi L; Bagnoli P
Exp Eye Res; 2013 Jun; 111():27-35. PubMed ID: 23528535
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
14. Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial.
Bührer C; Erdeve Ö; Bassler D; Bar-Oz B
BMJ Open; 2018 Jul; 8(7):e021749. PubMed ID: 29982217
[TBL] [Abstract][Full Text] [Related]
15. Retinal vascular development in an immature retina at 33-34 weeks postmenstrual age predicts retinopathy of prematurity.
Jang JH; Kim YC
Sci Rep; 2020 Oct; 10(1):18111. PubMed ID: 33093504
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge.
Cavallaro G; Filippi L; Bagnoli P; La Marca G; Cristofori G; Raffaeli G; Padrini L; Araimo G; Fumagalli M; Groppo M; Dal Monte M; Osnaghi S; Fiorini P; Mosca F
Acta Ophthalmol; 2014 Feb; 92(1):2-20. PubMed ID: 23617889
[TBL] [Abstract][Full Text] [Related]
17. Educational paper: Retinopathy of prematurity.
Casteels I; Cassiman C; Van Calster J; Allegaert K
Eur J Pediatr; 2012 Jun; 171(6):887-93. PubMed ID: 22052209
[TBL] [Abstract][Full Text] [Related]
18. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives.
Filippi L; Cavallaro G; Bagnoli P; Dal Monte M; Fiorini P; Donzelli G; Tinelli F; Araimo G; Cristofori G; la Marca G; Della Bona ML; La Torre A; Fortunato P; Furlanetto S; Osnaghi S; Mosca F
J Pediatr; 2013 Dec; 163(6):1570-1577.e6. PubMed ID: 24054431
[TBL] [Abstract][Full Text] [Related]
19. Update in the Treatment of Retinopathy of Prematurity.
Bancalari A; Schade R
Am J Perinatol; 2022 Jan; 39(1):22-30. PubMed ID: 32544962
[TBL] [Abstract][Full Text] [Related]
20. Propranolol ameliorates retinopathy of prematurity in mice by downregulating HIF-1α via the PI3K/Akt/ERK pathway.
Su S; Zou P; Yang G; Wang Y; Liu L; Liu Y; Zhang J; Ding Y
Pediatr Res; 2023 Apr; 93(5):1250-1257. PubMed ID: 35986147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
